Navigation Links
SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System
Date:5/19/2009

VANCOUVER, May 19 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific Corporation (NYSE: BSX) has reported positive outcomes from a substudy of patients with left main coronary disease who were treated with the TAXUS(R) Express(2)(R) Paclitaxel-Eluting Coronary Stent System. SYNTAX-LE MANS is a substudy of the landmark SYNTAX trial, the first randomized, controlled clinical trial to compare percutaneous coronary intervention (PCI) using the TAXUS Stent to coronary artery bypass graft (CABG) surgery in patients with left main disease and/or significant narrowing of all three coronary arteries (three-vessel disease). The substudy data were presented by A. Pieter Kappetein, M.D., Ph.D., at the annual EuroPCR Scientific Program in Barcelona.

SYNTAX-LE MANS compares late angiographic and clinical outcomes in 263 patients with left main disease (149 treated with the TAXUS Stent and 114 treated with CABG). It is designed to assess 15-month patency (vessel openness) and the safety of stents and grafts in this high-risk population; it includes separate primary endpoints for each treatment arm. For PCI patients, the primary endpoint is the rate of long-term patency (defined here as (less than)50% stenosis) of the treated lesion sites. For CABG patients, the primary endpoint is the ratio of obstructed/occluded grafts (defined here as (greater than or equal to)50% stenosis) to total placed grafts. Results were presented separately for each group, and no formal statistical inferences between the two groups were made due to the different primary endpoints. Results were also broken out by left main lesion location, including distal and non-distal.

For those patients receiving a TA
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery
2. Boston Scientific Welcomes Launch of Syntax Score Website
3. 3 strikes, youre out? Refiling of Amendment to Change Constitution to Criminalize Stem Cell Cures Shows Trouble with Anti-Cures Cause
4. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
5. International Survey Shows People Over Forty Ignore Risk of Blindness
6. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
7. New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
8. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
9. Video shows buckyballs form by shrink wrapping
10. National Survey Shows Most Women Are Not Satisfied With Their Progesterone Treatment
11. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... Services Staff members will be attending Pharma Ed Resources upcoming educational seminar ... group of industry leading speakers, this timely conference will provide Updates & Case ...
(Date:9/1/2015)... September 2, 2015 ... die Forschung und Entwicklung neuartiger Therapien für ... Darmerkrankungen und Reizdarm konzentriert, erhält vom US ... sein neues Medikament patentiert wird. Das Medikament ... bei Kindern verhindert und Entzündungen vorbeugt.   ...
(Date:9/1/2015)... , Sept. 1, 2015 Prostate ... death in American men. One in seven ... 233,000 new cases are diagnosed annually. That said, ... using a powerful new technique, MRI Fusion Biopsy, ... large cancer lesions, treating only the affected areas ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... joint disease. , Equine cervical facet joint problems can be caused by ... and can cause impingement of nerve roots or of the spinal cord itself. ...
Breaking Biology Technology:Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2September Is Prostate Cancer Awareness Month 2September Is Prostate Cancer Awareness Month 3September Is Prostate Cancer Awareness Month 4VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3
... Strong Growth in First-Half Revenue, up 9.4%, ... Essilor International, the world leader in ophthalmic optics, today,announced consolidated ... June 30, 2009, representing a reported 9.4% increase on,first-half 2008. ... was up 5.3% excluding the currency effect alone. , ...
... Mass., July 16 Caliper Life Sciences, Inc. (Nasdaq: ... quarter 2009 financial results at 9:00 a.m. ET on Thursday, July ... McAree, Chief Financial Officer, will host the call. Management will discuss ... , , A news release ...
... BUDAPEST, July 16 , - Introductory Webinar, ... at US User Group Meeting; September 15-16, San Diego,CA , ... the launch of JChem for Excel. The add-in for Microsoft Excel(R),brings ... to Excel(R) users. The product will be introduced at a free ...
Cached Biology Technology:Essilor : First Half 2009 Revenue 2Essilor : First Half 2009 Revenue 3Essilor : First Half 2009 Revenue 4Essilor : First Half 2009 Revenue 5Caliper Life Sciences' Second Quarter 2009 Financial Results Conference Call Notice 2ChemAxon Launches JChem for Excel 2
(Date:8/12/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is proud to announce that ... eClinical technology platform, has led the way to significant ... of 2015.   Q2 2015 and Q1 2015 were, ... contract value sold in the company,s 15 year history.  ...
(Date:8/10/2015)... , August 10, 2015 ... Eye Tracking Technology for more than two decades, announces ... for integration into all consumer display formats. The SMI ... integration of eye tracking into consumer tablets, laptops, desktop ... smart glasses. Omnivision,s leading sensor technology contributes to the ...
(Date:8/5/2015)... 5, 2015 According to a ... Market by Software, Services, Vertical (BFSI, Airport, IT & Telecom, ... Global Forecast to 2020", published by MarketsandMarkets, defines and ... into various segments. The global PIAM Market is estimated ... Million by 2019, at a CAGR of 14.9 % ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... Pa., Jan. 5, 2011 Unisys ... predictions for 2011. Over the next year, Unisys predicts, six ... move into greater everyday use in the enterprise as organizations ... and their mission-critical systems more secure and cost-efficient. ...
... One of Britain,s best known seabirds winters on opposite ... attempt has been successful according to new research published ... Society B . The findings highlight previously unsuspected ... kittiwakes. The research team was led by ...
... According to recent news reports, the next venue for ... to contaminate the food supplies of U.S. hotels and ... in hotel, restaurant, institution management and dietetics from Kansas ... bioterrorism. His dissertation, "Food Defense Management Practices In Private ...
Cached Biology News:From Disruptive to Productive: Unisys Predicts 2011 to be Year of Practical Application of Cutting-Edge Technologies 2From Disruptive to Productive: Unisys Predicts 2011 to be Year of Practical Application of Cutting-Edge Technologies 3From Disruptive to Productive: Unisys Predicts 2011 to be Year of Practical Application of Cutting-Edge Technologies 4From Disruptive to Productive: Unisys Predicts 2011 to be Year of Practical Application of Cutting-Edge Technologies 5Kittiwakes' trans-Atlantic winter odyssey linked to breeding success 2K-State doctoral graduate examines food bioterrorism for dissertation 2
... Precision-designed for Optimal Microdissection , CapSure HS ... precise and rapid extraction of populations of ... samples with Laser Capture Microdissection., Ensure ... Molecular Analysis , All CapSure LCM Caps ...
... Microdissection , CapSure HS and CapSure Macro ... extraction of populations of pure cells from ... Capture Microdissection., Ensure the Integrity of ... All CapSure LCM Caps have a patented ...
... detector is an optical unit that can ... or Dyad Disciple gradient-capable thermal cycler (purchased ... photonics shuttle that contains four LEDs for ... nm, 620-650 nm) and two filtered photodiodes ...
... sensitive laser confocal systems designed for rapid ... that meet your expectations, differentiating between a ... the signal on the bottom as well ... for increased sensitivity. Results with VersArray ChipReader ...
Biology Products: